BNP Paribas Exane cuts Itron stock price target on valuation shift

BNP Paribas Exane cut its Itron price target to $105 from $115 but maintained an Outperform rating, citing a lower valuation multiple and shifting its basis from 2027 to 2028 EV/EBITDA. The analyst sees AMI 1.0 meter replacement as a growth driver: Itron revenue could approach or exceed $3 billion in 2029–2030 versus $2.3 billion currently, as annual spending potentially tops $250 per meter. Separately, Itron’s Q3 2026 non-GAAP EPS of $1.94 beat the $1.56 forecast and revenue was $599.3 million, though shares declined slightly in premarket trading.

Analysis

The key investment question is whether lifecycle-driven replacement becomes funded, awarded orders—not whether old meters eventually need replacing. Itron can benefit as utilities move from AMI 1.0 servicing toward replacement, but the revenue path is exposed to regulatory approval, procurement timing, and installation capacity. Large programs could create order and revenue lumpiness; gradual annual replacement plans offer a steadier base but may be contested by Landis+Gyr and other meter suppliers, limiting pricing power. Also, replacement may reduce legacy servicing revenue, so the net benefit depends on contract economics and whether new deployments sustain margins.

Near term, recent execution supports the operating case, but the lower valuation multiple signals that the analyst is discounting a longer, less certain conversion cycle. Over 1–3 months, watch order intake, backlog conversion, and guidance for evidence that utility demand is translating into awards. The larger catalyst is regulatory and procurement progress, including the SCE decision expected in 2H27; the material revenue opportunity described is primarily a 2029–30 and later story. DTE’s gradual replacement trajectory supports demand visibility, but is not by itself evidence of a near-term earnings step-up.

Contrarian point: a 20-year asset-life threshold creates a compelling replacement narrative, but utilities can defer capex, phase deployments, or seek lower-cost bids. Revenue growth therefore need not translate proportionally into earnings growth. The thesis weakens if approvals or awards slip, Itron’s backlog fails to convert, or margins fall as competition intensifies.

Key Decisions for Investors

• Consider a measured long ITRI on weakness rather than chasing the lifecycle theme: the upside case relies on multi-year contract conversion, while the near-term catalyst is less certain. Size it as a growth-execution position, not as a near-term replacement-cycle certainty.
• Track quarterly bookings, backlog conversion, gross and adjusted EBITDA margins, and guidance. Treat the thesis as unconfirmed if revenue growth is driven by shipments without sustained margin performance or if management signals award delays.
• Set alerts for utility approval and procurement milestones, especially SCE’s expected 2H27 decision. A delay, reduced project scope, or staged award would push the expected revenue inflection further out and challenge the valuation case.
• Avoid treating DTE as a direct beneficiary trade: its replacement program may support Itron demand, but DTE’s own economics depend on regulatory recovery and the pace and cost of its capex.